rivastigmine 13.3 MG/Day 24HR Transdermal Patch
- RxCUI
- 1308569
- RxNorm name
- rivastigmine 13.3 MG/Day 24HR Transdermal Patch
- Display name
- rivastigmine 13.3 MG/Day 24HR Transdermal Patch
- Full name
- rivastigmine 13.3 MG/Day 24HR Transdermal Patch
- Term type
- SY
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:00
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Rivastigmine | RIVASTIGMINE | Zydus Lifesciences Limited | 966d59ea-5cea-4fef-8b96-e0efe885caf4 | 2025-11-17 | 1308569 | |
| Rivastigmine | RIVASTIGMINE | Northstar Rx LLC. | 8b809739-8381-4cc1-ab4a-5b17ab902a3d | 2025-11-14 | Warnings, Adverse reactions | 1308569 |
| Rivastigmine Transdermal System | RIVASTIGMINE | Bryant Ranch Prepack | 8d8823c0-9339-4ec8-8a19-d13974b6614b | 2025-04-01 | Warnings, Adverse reactions | 1308569 |
| Rivastigmine Transdermal System | RIVASTIGMINE | Bryant Ranch Prepack | 5cd5c434-ffd0-4aed-9eba-145c86b115bb | 2025-03-27 | Warnings, Adverse reactions | 1308569 |
| Rivastigmine Transdermal System | RIVASTIGMINE | Bryant Ranch Prepack | 6cc286d9-c5d4-4505-83bb-9015e3077851 | 2025-03-19 | Warnings, Adverse reactions | 1308569 |
| Rivastigmine Transdermal System | RIVASTIGMINE | Breckenridge Pharmaceutical, Inc. | b201fe68-b5e5-4a6f-8cf1-069543f03e76 | 2025-01-15 | Warnings, Adverse reactions | 1308569 |
| Rivastigmine | RIVASTIGMINE | Mylan Pharmaceuticals Inc. | 4ab335d1-19ee-4cd9-9776-8086645d19e4 | 2024-09-21 | Warnings, Adverse reactions | 1308569 |
| Rivastigmine | RIVASTIGMINE | Amneal Pharmaceuticals LLC | 8b671fc9-8cb0-4406-a9ee-7c95086d6200 | 2024-07-02 | Warnings, Adverse reactions | 1308569 |
| Rivastigmine | RIVASTIGMINE | Zydus Pharmaceuticals USA Inc. | 64dad603-2389-456b-8c18-d1d40b7e7419 | 2024-05-27 | Warnings, Adverse reactions | 1308569 |
| Rivastigmine | RIVASTIGMINE | Sandoz Inc | 92a58ebb-748d-49f4-bf11-ecbcf5424152 | 2024-05-08 | Warnings, Adverse reactions | 1308569 |
| Exelon | RIVASTIGMINE | Novartis Pharmaceuticals Corporation | 07c12e14-bbd5-4ec8-84e4-fbe7b5ba10e0 | 2024-05-08 | Warnings, Adverse reactions | 1308569 |
| Exelon | RIVASTIGMINE | Sandoz Inc | b6ed6d15-116d-4596-92ce-3414574d7ba0 | 2024-05-08 | Warnings, Adverse reactions | 1308569 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 5cd5c434-ffd0-4aed-9eba-145c86b115bb | rivastigmine 13.3 MG/Day 24HR Transdermal System | SY | 111 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. RIVASTIGMINE transdermal system Initial U.S. Approval: 2000 | 20250327 |
| 5cd5c434-ffd0-4aed-9eba-145c86b115bb | 24 HR rivastigmine 0.554 MG/HR Transdermal System | SCD | 111 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. RIVASTIGMINE transdermal system Initial U.S. Approval: 2000 | 20250327 |
| 5cd5c434-ffd0-4aed-9eba-145c86b115bb | rivastigmine 13.3 MG/Day 24HR Transdermal System | PSN | 111 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. RIVASTIGMINE transdermal system Initial U.S. Approval: 2000 | 20250327 |
| 5cd5c434-ffd0-4aed-9eba-145c86b115bb | rivastigmine 13.3 MG/Day 24HR Transdermal Patch | SY | 111 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. RIVASTIGMINE transdermal system Initial U.S. Approval: 2000 | 20250327 |
| 6cc286d9-c5d4-4505-83bb-9015e3077851 | rivastigmine 13.3 MG/Day 24HR Transdermal Patch | SY | 106 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. RIVASTIGMINE transdermal system Initial U.S. Approval: 2000 | 20250319 |
| 6cc286d9-c5d4-4505-83bb-9015e3077851 | rivastigmine 13.3 MG/Day 24HR Transdermal System | PSN | 106 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. RIVASTIGMINE transdermal system Initial U.S. Approval: 2000 | 20250319 |
| 6cc286d9-c5d4-4505-83bb-9015e3077851 | 24 HR rivastigmine 0.554 MG/HR Transdermal System | SCD | 106 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. RIVASTIGMINE transdermal system Initial U.S. Approval: 2000 | 20250319 |
| 6cc286d9-c5d4-4505-83bb-9015e3077851 | rivastigmine 13.3 MG/Day 24HR Transdermal System | SY | 106 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. RIVASTIGMINE transdermal system Initial U.S. Approval: 2000 | 20250319 |
| 8d8823c0-9339-4ec8-8a19-d13974b6614b | 24 HR rivastigmine 0.554 MG/HR Transdermal System | SCD | 102 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. RIVASTIGMINE transdermal system Initial U.S. Approval: 2000 | 20250401 |
| 8d8823c0-9339-4ec8-8a19-d13974b6614b | rivastigmine 13.3 MG/Day 24HR Transdermal System | SY | 102 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. RIVASTIGMINE transdermal system Initial U.S. Approval: 2000 | 20250401 |
| 8d8823c0-9339-4ec8-8a19-d13974b6614b | rivastigmine 13.3 MG/Day 24HR Transdermal System | PSN | 102 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. RIVASTIGMINE transdermal system Initial U.S. Approval: 2000 | 20250401 |
| 8d8823c0-9339-4ec8-8a19-d13974b6614b | rivastigmine 13.3 MG/Day 24HR Transdermal Patch | SY | 102 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. RIVASTIGMINE transdermal system Initial U.S. Approval: 2000 | 20250401 |
| 07c12e14-bbd5-4ec8-84e4-fbe7b5ba10e0 | 24 HR rivastigmine 0.554 MG/HR Transdermal System | SCD | 30 | These highlights do not include all the information needed to use EXELON PATCH safely and effectively. See full prescribing information for EXELON PATCH. EXELON ® PATCH (rivastigmine transdermal system) Initial U.S. Approval: 2000 | 20240508 |
| 07c12e14-bbd5-4ec8-84e4-fbe7b5ba10e0 | rivastigmine 13.3 MG/Day 24HR Transdermal System | PSN | 30 | These highlights do not include all the information needed to use EXELON PATCH safely and effectively. See full prescribing information for EXELON PATCH. EXELON ® PATCH (rivastigmine transdermal system) Initial U.S. Approval: 2000 | 20240508 |
| 07c12e14-bbd5-4ec8-84e4-fbe7b5ba10e0 | rivastigmine 13.3 MG/Day 24HR Transdermal System | SY | 30 | These highlights do not include all the information needed to use EXELON PATCH safely and effectively. See full prescribing information for EXELON PATCH. EXELON ® PATCH (rivastigmine transdermal system) Initial U.S. Approval: 2000 | 20240508 |
| 07c12e14-bbd5-4ec8-84e4-fbe7b5ba10e0 | rivastigmine 13.3 MG/Day 24HR Transdermal Patch | SY | 30 | These highlights do not include all the information needed to use EXELON PATCH safely and effectively. See full prescribing information for EXELON PATCH. EXELON ® PATCH (rivastigmine transdermal system) Initial U.S. Approval: 2000 | 20240508 |
| 8b671fc9-8cb0-4406-a9ee-7c95086d6200 | rivastigmine 13.3 MG/Day 24HR Transdermal System | SY | 17 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. RIVASTIGMINE transdermal system Initial U.S. Approval: 2000 | 20240702 |
| 8b671fc9-8cb0-4406-a9ee-7c95086d6200 | rivastigmine 13.3 MG/Day 24HR Transdermal Patch | SY | 17 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. RIVASTIGMINE transdermal system Initial U.S. Approval: 2000 | 20240702 |
| 8b671fc9-8cb0-4406-a9ee-7c95086d6200 | rivastigmine 13.3 MG/Day 24HR Transdermal System | PSN | 17 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. RIVASTIGMINE transdermal system Initial U.S. Approval: 2000 | 20240702 |
| 8b671fc9-8cb0-4406-a9ee-7c95086d6200 | 24 HR rivastigmine 0.554 MG/HR Transdermal System | SCD | 17 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. RIVASTIGMINE transdermal system Initial U.S. Approval: 2000 | 20240702 |
| 4ab335d1-19ee-4cd9-9776-8086645d19e4 | rivastigmine 13.3 MG/Day 24HR Transdermal System | SY | 10 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. RIVASTIGMINE transdermal system Initial U.S. Approval: 2000 | 20240921 |
| 4ab335d1-19ee-4cd9-9776-8086645d19e4 | rivastigmine 13.3 MG/Day 24HR Transdermal System | PSN | 10 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. RIVASTIGMINE transdermal system Initial U.S. Approval: 2000 | 20240921 |
| 4ab335d1-19ee-4cd9-9776-8086645d19e4 | rivastigmine 13.3 MG/Day 24HR Transdermal Patch | SY | 10 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. RIVASTIGMINE transdermal system Initial U.S. Approval: 2000 | 20240921 |
| 4ab335d1-19ee-4cd9-9776-8086645d19e4 | 24 HR rivastigmine 0.554 MG/HR Transdermal System | SCD | 10 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. RIVASTIGMINE transdermal system Initial U.S. Approval: 2000 | 20240921 |
| 8b809739-8381-4cc1-ab4a-5b17ab902a3d | rivastigmine 13.3 MG/Day 24HR Transdermal System | SY | 7 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. Rivastigmine Transdermal System Initial U.S. Approval: 2000 | 20251114 |
| 8b809739-8381-4cc1-ab4a-5b17ab902a3d | rivastigmine 13.3 MG/Day 24HR Transdermal System | PSN | 7 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. Rivastigmine Transdermal System Initial U.S. Approval: 2000 | 20251114 |
| 8b809739-8381-4cc1-ab4a-5b17ab902a3d | rivastigmine 13.3 MG/Day 24HR Transdermal Patch | SY | 7 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. Rivastigmine Transdermal System Initial U.S. Approval: 2000 | 20251114 |
| 8b809739-8381-4cc1-ab4a-5b17ab902a3d | 24 HR rivastigmine 0.554 MG/HR Transdermal System | SCD | 7 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. Rivastigmine Transdermal System Initial U.S. Approval: 2000 | 20251114 |
| b201fe68-b5e5-4a6f-8cf1-069543f03e76 | rivastigmine 13.3 MG/Day 24HR Transdermal Patch | SY | 7 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. RIVASTIGMINE transdermal system Initial U.S. Approval: 2000 | 20250115 |
| b201fe68-b5e5-4a6f-8cf1-069543f03e76 | 24 HR rivastigmine 0.554 MG/HR Transdermal System | SCD | 7 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. RIVASTIGMINE transdermal system Initial U.S. Approval: 2000 | 20250115 |
| b201fe68-b5e5-4a6f-8cf1-069543f03e76 | rivastigmine 13.3 MG/Day 24HR Transdermal System | SY | 7 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. RIVASTIGMINE transdermal system Initial U.S. Approval: 2000 | 20250115 |
| b201fe68-b5e5-4a6f-8cf1-069543f03e76 | rivastigmine 13.3 MG/Day 24HR Transdermal System | PSN | 7 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. RIVASTIGMINE transdermal system Initial U.S. Approval: 2000 | 20250115 |
| 92a58ebb-748d-49f4-bf11-ecbcf5424152 | rivastigmine 13.3 MG/Day 24HR Transdermal Patch | SY | 5 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. RIVASTIGMINE TRANSDERMAL SYSTEM Initial U.S. Approval: 2000 | 20240508 |
| 92a58ebb-748d-49f4-bf11-ecbcf5424152 | rivastigmine 13.3 MG/Day 24HR Transdermal System | PSN | 5 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. RIVASTIGMINE TRANSDERMAL SYSTEM Initial U.S. Approval: 2000 | 20240508 |
| 92a58ebb-748d-49f4-bf11-ecbcf5424152 | 24 HR rivastigmine 0.554 MG/HR Transdermal System | SCD | 5 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. RIVASTIGMINE TRANSDERMAL SYSTEM Initial U.S. Approval: 2000 | 20240508 |
| 92a58ebb-748d-49f4-bf11-ecbcf5424152 | rivastigmine 13.3 MG/Day 24HR Transdermal System | SY | 5 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. RIVASTIGMINE TRANSDERMAL SYSTEM Initial U.S. Approval: 2000 | 20240508 |
| 64dad603-2389-456b-8c18-d1d40b7e7419 | rivastigmine 13.3 MG/Day 24HR Transdermal Patch | SY | 4 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. Rivastigmine Transdermal System Initial U.S. Approval: 2000 | 20240527 |
| 64dad603-2389-456b-8c18-d1d40b7e7419 | rivastigmine 13.3 MG/Day 24HR Transdermal System | SY | 4 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. Rivastigmine Transdermal System Initial U.S. Approval: 2000 | 20240527 |
| 64dad603-2389-456b-8c18-d1d40b7e7419 | 24 HR rivastigmine 0.554 MG/HR Transdermal System | SCD | 4 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. Rivastigmine Transdermal System Initial U.S. Approval: 2000 | 20240527 |
| 64dad603-2389-456b-8c18-d1d40b7e7419 | rivastigmine 13.3 MG/Day 24HR Transdermal System | PSN | 4 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. Rivastigmine Transdermal System Initial U.S. Approval: 2000 | 20240527 |
| 7d8414f5-b51f-4ccb-b7a1-83b9ede5b266 | 24 HR rivastigmine 0.554 MG/HR Transdermal System | SCD | 3 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. Rivastigmine Transdermal System Initial U.S. Approval: 2000 | 20221004 |
| 7d8414f5-b51f-4ccb-b7a1-83b9ede5b266 | rivastigmine 13.3 MG/Day 24HR Transdermal Patch | SY | 3 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. Rivastigmine Transdermal System Initial U.S. Approval: 2000 | 20221004 |
| 7d8414f5-b51f-4ccb-b7a1-83b9ede5b266 | rivastigmine 13.3 MG/Day 24HR Transdermal System | PSN | 3 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. Rivastigmine Transdermal System Initial U.S. Approval: 2000 | 20221004 |
| 7d8414f5-b51f-4ccb-b7a1-83b9ede5b266 | rivastigmine 13.3 MG/Day 24HR Transdermal System | SY | 3 | These highlights do not include all the information needed to use RIVASTIGMINE TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for RIVASTIGMINE TRANSDERMAL SYSTEM. Rivastigmine Transdermal System Initial U.S. Approval: 2000 | 20221004 |
| 966d59ea-5cea-4fef-8b96-e0efe885caf4 | 24 HR rivastigmine 0.554 MG/HR Transdermal System | SCD | 1 | Rivastigmine Transdermal System | 20251117 |
| 966d59ea-5cea-4fef-8b96-e0efe885caf4 | rivastigmine 13.3 MG/Day 24HR Transdermal Patch | SY | 1 | Rivastigmine Transdermal System | 20251117 |
| 966d59ea-5cea-4fef-8b96-e0efe885caf4 | rivastigmine 13.3 MG/Day 24HR Transdermal System | PSN | 1 | Rivastigmine Transdermal System | 20251117 |
| 966d59ea-5cea-4fef-8b96-e0efe885caf4 | rivastigmine 13.3 MG/Day 24HR Transdermal System | SY | 1 | Rivastigmine Transdermal System | 20251117 |
| b6ed6d15-116d-4596-92ce-3414574d7ba0 | rivastigmine 13.3 MG/Day 24HR Transdermal Patch | SY | 1 | These highlights do not include all the information needed to use EXELON PATCH safely and effectively. See full prescribing information for EXELON PATCH. EXELON ® PATCH (rivastigmine transdermal system) Initial U.S. Approval: 2000 | 20240508 |
| b6ed6d15-116d-4596-92ce-3414574d7ba0 | rivastigmine 13.3 MG/Day 24HR Transdermal System | SY | 1 | These highlights do not include all the information needed to use EXELON PATCH safely and effectively. See full prescribing information for EXELON PATCH. EXELON ® PATCH (rivastigmine transdermal system) Initial U.S. Approval: 2000 | 20240508 |
| b6ed6d15-116d-4596-92ce-3414574d7ba0 | 24 HR rivastigmine 0.554 MG/HR Transdermal System | SCD | 1 | These highlights do not include all the information needed to use EXELON PATCH safely and effectively. See full prescribing information for EXELON PATCH. EXELON ® PATCH (rivastigmine transdermal system) Initial U.S. Approval: 2000 | 20240508 |
| b6ed6d15-116d-4596-92ce-3414574d7ba0 | rivastigmine 13.3 MG/Day 24HR Transdermal System | PSN | 1 | These highlights do not include all the information needed to use EXELON PATCH safely and effectively. See full prescribing information for EXELON PATCH. EXELON ® PATCH (rivastigmine transdermal system) Initial U.S. Approval: 2000 | 20240508 |